US-based Arcturus working with Duke-NUS on single-dose Covid-19 vaccine plans phase 3 trials

More than 354 million doses of various Covid-19 vaccines have reportedly been administered across 121 countries. PHOTO: ST FILE
New: Gift this subscriber-only story to your friends and family

SINGAPORE - United States-based Arcturus Therapeutics, which is jointly developing a Covid-19 vaccine with the Duke-NUS Medical School in Singapore, is preparing to test a single low-dose shot of its messenger RNA vaccine in large trials that will start in the second quarter of the year.

The 5 microgram single-dose regimen will also be a lyophilised, or freeze-dried, version that will be easier and less costly to distribute and store. It will not require the cold chain storage and transport that the usual mRNA vaccine in frozen liquid form needs.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.